{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:15Z","timestamp":1791924435677,"version":"4.3.4"},"reference-count":50,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001445","name":"Alex\u2019s Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["521-23536"],"award-info":[{"award-number":["521-23536"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["MRSG-16-196-01-LIB"],"award-info":[{"award-number":["MRSG-16-196-01-LIB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,6,21]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adoptive transfer of chimeric antigen receptor (CAR)-expressing natural killer (NK) cells has demonstrated success against hematological malignancies. Efficacy against solid tumors has been limited by poor NK cell survival and function in the suppressive tumor microenvironment (TME). To enhance efficacy against solid tumors, stimulatory cytokines have been incorporated into CAR-NK cell therapeutic approaches. However, current cytokine strategies have limitations, including systemic toxicities, exogenous dependencies, and unwanted TME bystander effects. Here, we aimed to overcome these limitations by modifying CAR-NK cells to express a constitutively active interleukin (IL)-7 receptor, termed C7R, capable of providing intrinsic CAR-NK cell activation that does not rely on or produce exogenous signals nor activate bystander cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We examined persistence, antitumor function, and transcriptional profiles of CAR-NK cells coexpressing C7R in a novel tumor immune microenvironment (TiME) co-culture system and against hematologic and solid tumor xenografts in vivo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Peripheral blood NK cells expressing a CAR directed against the solid tumor antigen GD2 and modified with C7R demonstrated enhanced tumor killing and persistence in vitro compared with CAR-NK cells without cytokine support and similar functions to CAR-NK cells supplemented with recombinant IL-15. C7R.CAR-NK cells exhibited enhanced survival and proliferation within neuroblastoma TiME xenografts in vivo but produced poor long-term tumor control compared with CAR-NK cells supplemented with IL-15. Similar results were seen using C7R-expressing CD19.CAR-NK cells against CD19+leukemia xenografts. Gene expression analysis revealed that chronic signaling via C7R induced a transcriptional signature consistent with intratumor stressed NK cells with blunted effector function. We identified gene candidates associated with chronic cytokine-stressed NK cells that could be targeted to reduce CAR-NK cell stress within the solid TME.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>C7R promoted CAR-NK cell survival in hostile TMEs independent of exogenous signals but resulted in poor antitumor function in vivo. Our data reveals the detrimental role of continuous IL-7 signaling in CAR-NK cells and provides insights into proper application of cytokine signals when attempting to enhance CAR-NK cell antitumor activity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-010672","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T06:50:19Z","timestamp":1753339819000},"page":"e010672","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control"],"prefix":"10.1136","volume":"13","author":[{"given":"Matthew","family":"Dysthe","sequence":"first","affiliation":[{"name":"Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishwar","family":"Navin","sequence":"additional","affiliation":[{"name":"Immunology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayenne","family":"van Leeuwen","sequence":"additional","affiliation":[{"name":"Immunology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josue","family":"Pineda","sequence":"additional","affiliation":[{"name":"Pediatrics-Oncology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Pediatrics-Oncology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-2864","authenticated-orcid":false,"given":"Cliona M","family":"Rooney","sequence":"additional","affiliation":[{"name":"Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Immunology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Pediatrics-Oncology, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-6713","authenticated-orcid":false,"given":"Robin","family":"Parihar","sequence":"additional","affiliation":[{"name":"Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Immunology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Pediatrics-Oncology, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2025100302290340000_13.7.e010672.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8"},{"key":"2025100302290340000_13.7.e010672.2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384039","article-title":"Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"key":"2025100302290340000_13.7.e010672.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80664-0"},{"key":"2025100302290340000_13.7.e010672.4","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2010.515582"},{"key":"2025100302290340000_13.7.e010672.5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028332"},{"key":"2025100302290340000_13.7.e010672.6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704086"},{"key":"2025100302290340000_13.7.e010672.7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.2021011532","article-title":"Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy","volume":"139","author":"Berrien-Elliott","year":"2022","journal-title":"Blood"},{"key":"2025100302290340000_13.7.e010672.8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226"},{"key":"2025100302290340000_13.7.e010672.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.07.007"},{"key":"2025100302290340000_13.7.e010672.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-037473"},{"key":"2025100302290340000_13.7.e010672.11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0732"},{"key":"2025100302290340000_13.7.e010672.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-291633"},{"key":"2025100302290340000_13.7.e010672.13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0538"},{"key":"2025100302290340000_13.7.e010672.14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e3181cd872d","article-title":"IL-7 Enhances Survival of Human CD56bright NK Cells","volume":"33","author":"Michaud","year":"2010","journal-title":"J Immunother"},{"key":"2025100302290340000_13.7.e010672.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1882"},{"key":"2025100302290340000_13.7.e010672.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03596.x"},{"key":"2025100302290340000_13.7.e010672.17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-1-4939-3684-7_16","article-title":"Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy","volume":"1441","author":"Lapteva","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2025100302290340000_13.7.e010672.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat Commun"},{"key":"2025100302290340000_13.7.e010672.19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2025100302290340000_13.7.e010672.20","unstructured":"Dysthe M M , Parihar R R . Data from: Human Immune Exhaustion Gene Expression Profile in C7R-CAR and CAR NK cells. NCBI GEO Repository. 2024 Available: https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE277499"},{"key":"2025100302290340000_13.7.e010672.21","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.080"},{"key":"2025100302290340000_13.7.e010672.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1466-y"},{"key":"2025100302290340000_13.7.e010672.23","doi-asserted-by":"crossref","unstructured":"Wu J , Gao F , Wang C , et al . IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma. J Exp Clin Cancer Res 2019;38. doi:10.1186\/s13046-019-1310-0","DOI":"10.1186\/s13046-019-1310-0"},{"key":"2025100302290340000_13.7.e010672.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-023-00789-0"},{"key":"2025100302290340000_13.7.e010672.25","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250050","article-title":"Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G","volume":"6","author":"Kailayangiri","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100302290340000_13.7.e010672.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8"},{"key":"2025100302290340000_13.7.e010672.27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.13611","article-title":"NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-\u03b3\/p-STAT1\/IRF1 pathway","volume":"169","author":"Yu","year":"2023","journal-title":"Immunology"},{"key":"2025100302290340000_13.7.e010672.28","doi-asserted-by":"crossref","unstructured":"Weisshaar N , Wu J , Ming Y . Rgs16 promotes antitumor CD8(+) T cell exhaustion. Sci Immunol 2022. doi:10.1126\/sciimmunol.abh1873","DOI":"10.1126\/sciimmunol.abh1873"},{"key":"2025100302290340000_13.7.e010672.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01884-z"},{"key":"2025100302290340000_13.7.e010672.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-019-0437-0","article-title":"Flipping the dogma - phosphatidylserine in non-apoptotic cell death","volume":"17","author":"Shlomovitz","year":"2019","journal-title":"Cell Commun Signal"},{"key":"2025100302290340000_13.7.e010672.31","article-title":"STATs in NK-Cells: The Good, the Bad, and the Ugly","volume":"7","author":"Gotthardt","year":"2016","journal-title":"Front Immunol"},{"key":"2025100302290340000_13.7.e010672.32","doi-asserted-by":"publisher","DOI":"10.3109\/15476910903453296"},{"key":"2025100302290340000_13.7.e010672.33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.161126098"},{"key":"2025100302290340000_13.7.e010672.34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020067"},{"key":"2025100302290340000_13.7.e010672.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"2025100302290340000_13.7.e010672.36","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell Discov"},{"key":"2025100302290340000_13.7.e010672.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.07.034"},{"key":"2025100302290340000_13.7.e010672.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.02.006"},{"key":"2025100302290340000_13.7.e010672.39","doi-asserted-by":"crossref","unstructured":"Wang X , Zhao XY . Transcription Factors Associated With IL-15 Cytokine Signaling During NK Cell Development. Front Immunol 2021. doi:10.3389\/fimmu.2021.610789","DOI":"10.3389\/fimmu.2021.610789"},{"key":"2025100302290340000_13.7.e010672.40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000699"},{"key":"2025100302290340000_13.7.e010672.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01883-0"},{"key":"2025100302290340000_13.7.e010672.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-44789-z","article-title":"Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity","volume":"15","author":"Dean","year":"2024","journal-title":"Nat Commun"},{"key":"2025100302290340000_13.7.e010672.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415364"},{"key":"2025100302290340000_13.7.e010672.44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","article-title":"Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction","volume":"567","author":"Liu","year":"2019","journal-title":"Nature New Biol"},{"key":"2025100302290340000_13.7.e010672.45","doi-asserted-by":"crossref","unstructured":"Sullivan MR , Finocchiaro M , Yang Y . An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells. J Immunother Cancer 2014. doi:10.1136\/jitc-2024-008912","DOI":"10.1136\/jitc-2024-008912"},{"key":"2025100302290340000_13.7.e010672.46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953849","article-title":"Overcoming tumor resistance mechanisms in CAR-NK cell therapy","volume":"13","author":"Valeri","year":"2022","journal-title":"Front Immunol"},{"key":"2025100302290340000_13.7.e010672.47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730970","article-title":"Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia","volume":"12","author":"Bou-Tayeh","year":"2021","journal-title":"Front Immunol"},{"key":"2025100302290340000_13.7.e010672.48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight"},{"key":"2025100302290340000_13.7.e010672.49","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.624122","article-title":"Role of the Orphan Nuclear Receptor NR4A Family in T-Cell Biology","volume":"11","author":"Odagiu","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025100302290340000_13.7.e010672.50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008665","article-title":"NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors","volume":"12","author":"Nakagawara","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:29:13Z","timestamp":1759483753000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,23]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2024-010672"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010672","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}